Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 1248 word(s) 1248 2020-12-02 09:36:29 |
2 format correct Meta information modification 1248 2020-12-18 05:00:49 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Audia, S.; Grienay, N.; Mounier, M.; Michel, M.; Bonnotte, B. Evans’ Syndrome. Encyclopedia. Available online: (accessed on 20 June 2024).
Audia S, Grienay N, Mounier M, Michel M, Bonnotte B. Evans’ Syndrome. Encyclopedia. Available at: Accessed June 20, 2024.
Audia, Sylvain, Natacha Grienay, Morgane Mounier, Marc Michel, Bernard Bonnotte. "Evans’ Syndrome" Encyclopedia, (accessed June 20, 2024).
Audia, S., Grienay, N., Mounier, M., Michel, M., & Bonnotte, B. (2020, December 18). Evans’ Syndrome. In Encyclopedia.
Audia, Sylvain, et al. "Evans’ Syndrome." Encyclopedia. Web. 18 December, 2020.
Evans’ Syndrome

Evans’ syndrome (ES) is defined as the concomitant or sequential association of warm auto-immune haemolytic anaemia (AIHA) with immune thrombocytopenia (ITP), and less frequently autoimmune neutropenia. ES is a rare situation that represents up to 7% of AIHA and around 2% of ITP. When AIHA and ITP occurred concomitantly, the diagnosis procedure must rule out differential diagnoses such as thrombotic microangiopathies, anaemia due to bleedings complicating ITP, vitamin deficiencies, myelodysplastic syndromes, paroxysmal nocturnal haemoglobinuria, or specific conditions like HELLP when occurring during pregnancy. As for isolated auto-immune cytopenia (AIC), the determination of the primary or secondary nature of ES is important. Indeed, the association of ES with other diseases such as haematological malignancies, systemic lupus erythematosus, infections, or primary immune deficiencies can interfere with its management or alter its prognosis. Due to the rarity of the disease, the treatment of ES is mostly extrapolated from what is recommended for isolated AIC and mostly relies on corticosteroids, rituximab, splenectomy, and supportive therapies.

autoimmune haemolytic anaemia immune thrombocytopenia Evans’ syndrome

1. Introduction

Evans’ syndrome (ES) was first described by Evans in 1951 [1] and is defined as the concomitant or sequential occurrence of immune thrombocytopenia (ITP) and autoimmune haemolytic anaemia (AIHA). ES-anaemia is an AIHA dues to warm antibodies that are usually of IgG isotype, exceptionally IgA, thus excluding cold agglutinins [2]. Autoimmune neutropenia (AIN) can also be part of ES, occurring in 15% cases in adults and 20% in children [3].

Due to the rarity of the disease, there is almost no clinical trials comparing treatment modalities and that most of the recommendations that are given here are extrapolated from those of isolated ITP or isolated AIHA.

2. Evans’ Syndrome in Adults

2.1. Diagnosis Procedure

Diagnosis of ES

The diagnosis of ES relies on the concomitant or sequential diagnosis of AIC, but the delay between AIC occurrence is not a limiting factor.

AIHA is suspected in case of anaemia (haemoglobin <11 g/dL for female and <12 g/dL for male) associated with reticulocytosis and with markers of haemolysis, i.e., elevated lactate dehydrogenase, low haptoglobin and elevated indirect bilirubin, with a positive direct antiglobulin test (DAT) for IgG with or without complement (C3d) as cold agglutinins are excluded from ES [4].

ITP remains a diagnosis of exclusion suspected in case of rapid onset thrombocytopenia not related to liver diseases (cirrhosis and portal hypertension), splenomegaly (haematological malignancies, Gaucher disease,…), drug-related thrombocytopenia, bone marrow deficiency (myelodysplastic syndromes, haematological malignancies, metastatic cancer,…) or inherited thrombocytopenia [5]. Due to the lack of specificity or sensitivity of the different assays, the detection and identification of antiplatelet antibodies is still not recommended in routine practice and should be restricted to difficult cases [5]. However, when using direct Monoclonal Antibody Immobilization Platelet Assay (MAIPA), a sensitivity and a specificity of up to 81% and 98% have been reported, making this technique attractive for the diagnosis procedure [6].

AIN is suspected when facing a neutrophil count <1.5 G/L, after exclusion of other causes of neutropenia (drug-induced neutropenia; viral infections such as cytomegalovirus (CMV), Epstein Barr Virus (EBV), Human Immunodeficiency Virus (HIV), parvovirus B19, and influenza; myelodysplastic syndrome or leukaemia) as there is no specific test for its diagnosis [7]. Antineutrophil antibodies are quite difficult to determine in clinical practice as tests have not been standardized yet [8]. When antineutrophil antibodies are detected, they usually target Fc gamma receptor (FcγR), most particularly CD16 (FcγRIII) and more rarely CD32 (FcγRII), or the integrin CD11b or the complement receptor 1 (CR1/CD35) [9].

To avoid difficulties in the interpretation of biological tests, it must be kept in mind that some of these investigations must be performed before treating patients. Notably, intravenous immunoglobulins (IVIg) preclude the correct quantification of serum IgG, and immunosuppressants interfere with T and B cell phenotyping [10].

2.2. Clinical Management of Adulthood ES

Due to the rarity of ES, no clear therapeutic regimen has been established. However, treatments are mostly extrapolated from those commonly used for isolated ITP and isolated AIHA, and are summarized in Table.

Table. Treatment approaches of Evans’ syndrome in adults.

Treatment AIHA/ES-Anaemia   ITP/ES-Thrombocytopenia   References
  Dosage/Recommendations Response Dosage/Recommendations Response  
Corticosteroids Prednisone 1 mg/kg/day (up to 1.5 mg/day) for 3–4 weeks, progressive tapering over 6 months Initial: 80%
Prolonged: 33%
Prednisone, 1 mg/kg/day for 3–4 weeks Initial: 60–80%
Prolonged: 20–30%
    Dexamethasone, 40 mg/day, 4 days Initial: 80%
Prolonged: 20–30%
Methylprednisolone 15 mg/kg/day for 3 days
(no more than 1 g/day)
Recommended for life-threatening situation
Unknown Methylprednisolone 15 mg/kg/day for 3 days
(no more than 1 g/day)
Recommended for life-threatening situation
Unknown [4][5]
IVIg 0.4 g/kg/day, 5 days Initial: 32% 1 g/kg/day, 2 days Initial: 90% [5][11][14][15]
Rituximab 375 mg/m2/week for 4 weeks or 1000 mg Day1 & 15 60–75% 375 mg/m2/week for 4 weeks or 1000 mg Day1 & 15 40–60% [3][16][17][18][19][20]
Splenectomy To be avoided in ALPS 70% To be avoided in ALPS 88% [4][21][22]
Azathioprine 2–2.5 mg/kg/day
(of interest for pregnancy)
56–71% 2–2.5 mg/kg/day
(of interest for pregnancy)
45% [3][23][19][22][24]
Cyclophosphamide 1–2 mg/kg/day
(50–200 mg/day)
70% 1–2 mg/kg/day
(50–200 mg/day)
60% [3][23][11][25]
Cyclosporin 2.5 mg/kg twice per day
(of interest for pregnancy)
58% 1.5–2.5 mg/kg twice per day
(of interest for pregnancy)
44–55% [3][23][11][19][26][27]
Mycophenolate 500–1000 mg twice per day 25–100% 500–1000 mg twice per day 45–60% [3][23][11][19][22][28][29][30][31]
Vinka-alkaloid ND ND Vinblastine: 10 mg/week
Vincristine: 1–2 mg/week
Initial: 41–86% [5][11][32][33]
Plasma exchange To be considered in life-threatening haemolysis as adjunctive therapy Not known Not recommended   [34][35][36]
Transfusion ABO-, Rh-, K- matched RBC   Platelets are not recommended except in life-threatening haemorrhage combined with immunomodulatory drugs   [4][5][37][38][39]
Anticoagulation Thromboprophylaxis with low molecular weight heparin recommended for in-patients with acute exacerbation   Stop if platelet count <50 G/L   [40][41][42][43]
Bone marrow stimulating agents Erythropoietin: to be considered in patients with unappropriated reticulocyte count or insufficient response upon immunomodulatory drugs
Increased risk of thrombosis: to avoid in patient with risk factors
70–80% Thrombopoietin receptor agonists: to be considered if ES-thrombocytopenia is the main problem
Increased risk of thrombosis: to avoid if active haemolysis or thrombosis
70–80% [44][45][46][47][48]

2.3. Management of ES during Pregnancy

The management of ES during pregnancy is challenging as most of the drugs that are usually used in ES are not recommended, notably rituximab and TPO-RA, even though few reports showed favourable outcomes [49][50].

During pregnancy, corticosteroids remain the cornerstone therapy due to their high efficiency and short delay of action.

IVIg are also useful to treat ES-thrombocytopenia but are not recommended for ES-anaemia.

Azathioprine can be efficient on both ES-thrombocytopenia and ES-anaemia and could be maintained in case of ES prior to pregnancy. However, due to its long delay of action, azathioprine is of poor interest in case of ES emerging during pregnancy.

Splenectomy can be efficient on both ES-anaemia and ES-thrombocytopenia but is challenging during pregnancy and should be performed during the second trimester when needed.

3. Conclusions

ES is a rare combination of AIHA and ITP that is associated in 50% of adult cases with various diseases such as SLE, haematological malignancies, or PID, the latter being the most frequent in children. Its prognosis is poorer than the one of isolated AIC and is particularly worse when associated with haematological malignancies. Its management is mostly empirical and extrapolated from guidelines for both isolated AIHA and isolated ITP. Corticosteroids remain the first line therapy with a short course duration for ES-thrombocytopenia and of six months for ES-anaemia. Second line treatments are usually required and the ones that are efficient in both isolated AIHA and isolated ITP such as rituximab, immunosuppressants, and splenectomy are recommended. In specific situations such as ALPS, mycophenolate mofetil or sirolimus should be preferred. Treatments that could be required for managing isolated ITP and that are associated with an increased risk of thrombosis such as IVIg and TPO-RA should be used with caution in ES as ES-anaemia probably increases the risk of thrombosis, as observed in isolated AIHA.


  1. Evans, R.S.; Takahashi, K.; Duane, R.T.; Payne, R.; Liu, C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch. Intern. Med. 1951, 87, 48–65.
  2. Moncharmont, P.; Troncy, J.; Rigal, D. IgA anti-red blood cell auto-antibodies in Evans syndrome. Hematology 2007, 12, 587–589.
  3. Michel, M.; Chanet, V.; Dechartres, A.; Morin, A.S.; Piette, J.C.; Cirasino, L.; Emilia, G.; Zaja, F.; Ruggeri, M.; Andres, E.; et al. The spectrum of Evans syndrome in adults: New insight into the disease based on the analysis of 68 cases. Blood 2009, 114, 3167–3172.
  4. Jager, U.; Barcellini, W.; Broome, C.M.; Gertz, M.A.; Hill, A.; Hill, Q.A.; Jilma, B.; Kuter, D.J.; Michel, M.; Montillo, M.; et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2019.
  5. Provan, D.; Arnold, D.M.; Bussel, J.B.; Chong, B.H.; Cooper, N.; Gernsheimer, T.; Ghanima, W.; Godeau, B.; Gonzalez-Lopez, T.J.; Grainger, J.; et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019, 3, 3780–3817.
  6. Porcelijn, L.; Huiskes, E.; Oldert, G.; Schipperus, M.; Zwaginga, J.J.; de Haas, M. Detection of platelet autoantibodies to identify immune thrombocytopenia: State of the art. Br. J. Haematol. 2018, 182, 423–426.
  7. Newburger, P.E. Autoimmune and other acquired neutropenias. Hematol. Am. Soc. Hematol. Educ. Program. 2016, 2016, 38–42.
  8. Lucas, G.; Rogers, S.; de Haas, M.; Porcelijn, L.; Bux, J. Report on the Fourth International Granulocyte Immunology Workshop: Progress toward quality assessment. Transfusion 2002, 42, 462–468.
  9. Youinou, P.; Jamin, C.; Le Pottier, L.; Renaudineau, Y.; Hillion, S.; Pers, J.O. Diagnostic criteria for autoimmune neutropenia. Autoimmun. Rev. 2014, 13, 574–576.
  10. Seidel, M.G. Autoimmune and other cytopenias in primary immunodeficiencies: Pathomechanisms, novel differential diagnoses, and treatment. Blood 2014, 124, 2337–2344.
  11. Neunert, C.; Terrell, D.R.; Arnold, D.M.; Buchanan, G.; Cines, D.B.; Cooper, N.; Cuker, A.; Despotovic, J.M.; George, J.N.; Grace, R.F.; et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019, 3, 3829–3866.
  12. Wei, Y.; Ji, X.B.; Wang, Y.W.; Wang, J.X.; Yang, E.Q.; Wang, Z.C.; Sang, Y.Q.; Bi, Z.M.; Ren, C.A.; Zhou, F.; et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: A prospective multicenter randomized trial. Blood 2016, 127, 296–302.
  13. Mithoowani, S.; Gregory-Miller, K.; Goy, J.; Miller, M.C.; Wang, G.; Noroozi, N.; Kelton, J.G.; Arnold, D.M. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: A systematic review and meta-analysis. Lancet Haematol. 2016, 3, e489–e496.
  14. Flores, G.; Cunningham-Rundles, C.; Newland, A.C.; Bussel, J.B. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: Results in 73 patients. Am. J. Hematol. 1993, 44, 237–242.
  15. Godeau, B.; Chevret, S.; Varet, B.; Lefrere, F.; Zini, J.M.; Bassompierre, F.; Cheze, S.; Legouffe, E.; Hulin, C.; Grange, M.J.; et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: A randomised, multicentre trial. Lancet 2002, 359, 23–29.
  16. Birgens, H.; Frederiksen, H.; Hasselbalch, H.C.; Rasmussen, I.H.; Nielsen, O.J.; Kjeldsen, L.; Larsen, H.; Mourits-Andersen, T.; Plesner, T.; Ronnov-Jessen, D.; et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br. J. Haematol. 2013, 163, 393–399.
  17. Michel, M.; Terriou, L.; Roudot-Thoraval, F.; Hamidou, M.; Ebbo, M.; Le Guenno, G.; Galicier, L.; Audia, S.; Royer, B.; Sophie Morin, A.; et al. A Randomized and Double-Blind Controlled Trial Evaluating the Safety and Efficacy of Rituximab for Warm Auto-Immune Hemolytic Anemia in Adults (the RAIHA study). Am. J. Hematol. 2016.
  18. Deshayes, S.; Khellaf, M.; Zarour, A.; Layese, R.; Fain, O.; Terriou, L.; Viallard, J.F.; Cheze, S.; Graveleau, J.; Slama, B.; et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. Am. J. Hematol. 2019, 94, 1314–1324.
  19. Aladjidi, N.; Fernandes, H.; Leblanc, T.; Vareliette, A.; Rieux-Laucat, F.; Bertrand, Y.; Chambost, H.; Pasquet, M.; Mazingue, F.; Guitton, C.; et al. Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort. Front. Pediatr. 2015, 3, 79.
  20. Bader-Meunier, B.; Aladjidi, N.; Bellmann, F.; Monpoux, F.; Nelken, B.; Robert, A.; Armari-Alla, C.; Picard, C.; Ledeist, F.; Munzer, M.; et al. Rituximab therapy for childhood Evans syndrome. Haematologica 2007, 92, 1691–1694.
  21. Kojouri, K.; Vesely, S.K.; Terrell, D.R.; George, J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004, 104, 2623–2634.
  22. Roumier, M.; Loustau, V.; Guillaud, C.; Languille, L.; Mahevas, M.; Khellaf, M.; Limal, N.; Noizat-Pirenne, F.; Godeau, B.; Michel, M. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. Am. J. Hematol. 2014, 89, E150–E155.
  23. Barcellini, W.; Fattizzo, B.; Zaninoni, A.; Radice, T.; Nichele, I.; Di Bona, E.; Lunghi, M.; Tassinari, C.; Alfinito, F.; Ferrari, A.; et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: A GIMEMA study of 308 patients. Blood 2014, 124, 2930–2936.
  24. Quiquandon, I.; Fenaux, P.; Caulier, M.T.; Pagniez, D.; Huart, J.J.; Bauters, F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: A report on 53 cases. Br. J. Haematol. 1990, 74, 223–228.
  25. Pizzuto, J.; Ambriz, R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 1984, 64, 1179–1183.
  26. Choudhary, D.R.; Naithani, R.; Mahapatra, M.; Kumar, R.; Mishra, P.; Saxena, R. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica 2008, 93, e61–e62.discussion e63.
  27. Kappers-Klunne, M.C.; van’t Veer, M.B. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br. J. Haematol. 2001, 114, 121–125.
  28. Miano, M.; Ramenghi, U.; Russo, G.; Rubert, L.; Barone, A.; Tucci, F.; Farruggia, P.; Petrone, A.; Mondino, A.; Lo Valvo, L.; et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br. J. Haematol. 2016, 175, 490–495.
  29. Neven, B.; Magerus-Chatinet, A.; Florkin, B.; Gobert, D.; Lambotte, O.; De Somer, L.; Lanzarotti, N.; Stolzenberg, M.C.; Bader-Meunier, B.; Aladjidi, N.; et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood 2011, 118, 4798–4807.
  30. Taylor, A.; Neave, L.; Solanki, S.; Westwood, J.P.; Terrinonive, I.; McGuckin, S.; Kothari, J.; Cooper, N.; Stasi, R.; Scully, M. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br. J. Haematol. 2015, 171, 625–630.
  31. Colovic, M.; Suvajdzic, N.; Colovic, N.; Tomin, D.; Vidovic, A.; Palibrk, V. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Platelets 2011, 22, 153–156.
  32. Stirnemann, J.; Kaddouri, N.; Khellaf, M.; Morin, A.S.; Prendki, V.; Michel, M.; Mekinian, A.; Bierling, P.; Fenaux, P.; Godeau, B.; et al. Vincristine efficacy and safety in treating immune thrombocytopenia: A retrospective study of 35 patients. Eur. J. Haematol. 2015.
  33. Audia, S.; Godeau, B.; Bonnotte, B. Is there still a place for “old therapies” in the management of immune thrombocytopenia? Rev. Med. Interne 2016, 37, 43–49.
  34. Ruivard, M.; Tournilhac, O.; Montel, S.; Fouilhoux, A.C.; Quainon, F.; Lenat, A.; Travade, P.; Philippe, P. Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: A retrospective case-control study. J. Clin. Apher. 2006, 21, 202–206.
  35. von Baeyer, H. Plasmapheresis in immune hematology: Review of clinical outcome data with respect to evidence-based medicine and clinical experience. Ther Apher. Dial. 2003, 7, 127–140.
  36. Padmanabhan, A.; Connelly-Smith, L.; Aqui, N.; Balogun, R.A.; Klingel, R.; Meyer, E.; Pham, H.P.; Schneiderman, J.; Witt, V.; Wu, Y.; et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J. Clin. Apher. 2019, 34, 171–354.
  37. Hill, Q.A.; Stamps, R.; Massey, E.; Grainger, J.D.; Provan, D.; Hill, A. The diagnosis and management of primary autoimmune haemolytic anaemia. Br. J. Haematol. 2017, 176, 395–411.
  38. Goel, R.; Chopra, S.; Tobian, A.A.R.; Ness, P.M.; Frank, S.M.; Cushing, M.; Vasovic, L.; Kaicker, S.; Takemoto, C.; Josephson, C.D.; et al. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion 2019, 59, 169–176.
  39. Spahr, J.E.; Rodgers, G.M. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: A retrospective review of 40 patients. Am. J. Hematol. 2008, 83, 122–125.
  40. Audia, S.; Bach, B.; Samson, M.; Lakomy, D.; Bour, J.B.; Burlet, B.; Guy, J.; Duvillard, L.; Branger, M.; Leguy-Seguin, V.; et al. Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS ONE 2018, 13, e0207218.
  41. Hendrick, A.M. Auto-immune haemolytic anaemia--a high-risk disorder for thromboembolism? Hematology 2003, 8, 53–56.
  42. Lecouffe-Desprets, M.; Graveleau, J.; Artifoni, M.; Connault, J.; Agard, C.; Pottier, P.; Hamidou, M.; Neel, A. Hemolytic disorders and venous thrombosis: An update. Rev. Med. Interne 2019, 40, 232–237.
  43. Yusuf, H.R.; Hooper, W.C.; Grosse, S.D.; Parker, C.S.; Boulet, S.L.; Ortel, T.L. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: A study among a U.S. cohort of commercial insurance enrollees. Thromb. Res. 2015, 135, 50–57.
  44. Fattizzo, B.; Michel, M.; Zaninoni, A.; Giannotta, J.; Guillet, S.; Frederiksen, H.; Vos, J.M.I.; Mauro, F.R.; Jilma, B.; Patriarca, A.; et al. Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: A multicentre international study. Haematologica 2020.
  45. Bussel, J.B.; Cheng, G.; Saleh, M.N.; Psaila, B.; Kovaleva, L.; Meddeb, B.; Kloczko, J.; Hassani, H.; Mayer, B.; Stone, N.L.; et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 2007, 357, 2237–2247.
  46. Kuter, D.J.; Bussel, J.B.; Lyons, R.M.; Pullarkat, V.; Gernsheimer, T.B.; Senecal, F.M.; Aledort, L.M.; George, J.N.; Kessler, C.M.; Sanz, M.A.; et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008, 371, 395–403.
  47. Gonzalez-Nieto, J.A.; Martin-Suarez, I.; Quattrino, S.; Ortiz-Lopez, E.; Munoz-Beamud, F.R.; Colchero-Fernandez, J.; Alcoucer-Diaz, M.R. The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab. Lupus 2011, 20, 1321–1323.
  48. Ruiz-Arguelles, G.J.; Ruiz-Delgado, G.J.; Velazquez-Sanchez-de-Cima, S.; Zamora-Ortiz, G. Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab. Hematology 2013, 18, 175–177.
  49. Michel, M.; Ruggeri, M.; Gonzalez-Lopez, T.J.; Alkindi, S.S.; Cheze, S.; Ghanima, W.; Tvedt, T.H.A.; Ebbo, M.; Terriou, L.; Bussel, J.B.; et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: Results from a multicenter study. Blood 2020.
  50. Martinez-Martinez, M.U.; Baranda-Candido, L.; Gonzalez-Amaro, R.; Perez-Ramirez, O.; Abud-Mendoza, C. Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman. Rheumatology (Oxford) 2013, 52, 405–406.
Subjects: Others
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , , , ,
View Times: 460
Revisions: 2 times (View History)
Update Date: 18 Dec 2020
Video Production Service